Ocular Therapeutix, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$30.2M
Doctors Paid
4,678
Transactions
16,572
2024 Total
$10.9M
Payment Breakdown by Category
Research$23.3M (77.1%)
Consulting$2.5M (8.4%)
Food & Beverage$450,517 (1.5%)
Travel$87,372 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23.3M | 2,260 | 77.1% |
| Consulting Fee | $2.5M | 743 | 8.4% |
| Current or prospective ownership or investment interest | $2.3M | 17 | 7.5% |
| Honoraria | $541,676 | 77 | 1.8% |
| Food and Beverage | $450,517 | 13,073 | 1.5% |
| Grant | $420,000 | 3 | 1.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $388,195 | 127 | 1.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $175,767 | 63 | 0.6% |
| Travel and Lodging | $87,372 | 159 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $10,500 | 2 | 0.0% |
| Long term medical supply or device loan | $7,025 | 33 | 0.0% |
| Education | $3,197 | 11 | 0.0% |
| Gift | $236.58 | 4 | 0.0% |
Payments by Type
Research
$23.3M
2,260 transactions
General
$6.9M
14,312 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | $7.2M | 0 | 635 |
| A Prospective, Multicenter, Randomized, Parallel-Arm, Double Masked, Vehicle Controlled Phase 3a Study Evaluating the Safety and Efficacy of OTX-TP in the Treatment of Subjects With Open-Angle Glaucoma or Ocular Hypertension | $3.5M | 0 | 610 |
| A Prospective, Multicenter, Randomized, Parallel-Arm, Double-Marked, Vehicle Controlled Phase 3 Study Evaluating the Safety and Efficacy of DEXTENZA for the treatment of Ocular Inflammation and Pain after Cataract Surgery | $1.5M | 0 | 191 |
| A Randomized, Double-Masked, Vehicle-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of OTX-DED (Dexamethasone Intracanalicular Ophthalmic Insert) for the Short-Term Treatment of Signs and Symptoms of Dry Eye Disease (DED) | $1.1M | 0 | 82 |
| A Randomized, Multi-center, Double-masked, Vehicle-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI (Cyclosporine Ophthalmic Insert) for Intracanalicular Use for the Treatment of Subjects With Dry Eye Disease (DED) | $946,944 | 0 | 103 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy | $620,676 | 0 | 102 |
| A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) | $610,077 | 2 | 25 |
| The SPENCER Study | $443,625 | 0 | 8 |
| Assessing the efficacy and safety of DEXTENZA, sustained release dexamtheasone 0.4mg insert, when placed within the lower and upper eye lid canaliculus in conjunction with topical prednisolone acetate 1% for the treatment of pain, and inflammation following corneal transplant surgery (PKP, DSEK, DMEK) as compared to topical prednisolone acetate 1% monotherapy | $396,790 | 0 | 61 |
| A Prospective Multicenter Open Label Study to Evaluate the Safety Tolerability and Efficacy of OTX TIC Implant in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension | $386,762 | 0 | 37 |
| In Clinic Optometrist Insertion of DEXTENZA Prior to Cataract Surgery | $353,184 | 0 | 9 |
| Open Label Study to Evaluate the Safety, Tolerability and Efficacy of OTX-TIC (Travoprost) Implant in Subjects with Primary Open-Angle Glaucoma or Ocular Hypertension | $278,545 | 0 | 11 |
| OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED) | $259,141 | 0 | 1 |
| A Prospective, Multicenter, Open Label Extension Study to Evaluate the Long Term Safety of OTX-TP | $256,921 | 0 | 9 |
| Assessing the efficacy and safey of DEXTENZA, Sustained release dexamethasone 0.4 mg insert, when placed within the lower eye lid canaliculus compared to loteprednol suspension for the treatment of episodic of dry eye | $231,580 | 0 | 6 |
| DEXTENZA Versus Topical Steroid or Antihistamine Therapy for Treatment of Allergic Conjunctivitis | $224,861 | 0 | 8 |
| Impaired Populations Project | $200,000 | 0 | 3 |
| Intracanalicular Dexamethasone used in conjunction with iLUX for the treatment of meibomian gland dysfunction in patients with evaporative dry eye disease and evidence of clinically significant inflammation | $191,945 | 0 | 8 |
| The AtLAS Study | $167,630 | 0 | 3 |
| A Randomized, Parallel-Arm, Active Control, Multi-Center Study Assessing the Safety And Efficacy Of Dextenza for the Treatment Of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract | $159,605 | 0 | 31 |
| Safety and Efficacy of Dexamethasone Ophthalmic Insert (Dextenza) in the Management of Clinically Significant Dry Eye | $155,056 | 0 | 5 |
| The RESTORE Study | $139,430 | 0 | 2 |
| The PRIME Study | $137,780 | 0 | 3 |
| Randomized, controlled treatment with an intracanaliuclar dexamethasone (0.4mg) insert following cataract surgery with intraocular lens implant (IOL) combined with minimally invasive glaucoma surgery (MIGS), specifically iStent, iStent inject or KDB in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHTN) | $137,200 | 0 | 4 |
| The NAVY Study (DEX in the DOD) | $125,000 | 0 | 2 |
| The pharmacokinetics of aqueous dexamethasone and the inflammatory cytokine response after treatment with a dexamethasone intracanalicular insert | $124,680 | 0 | 2 |
| The SITE Study | $122,959 | 1 | 6 |
| A Randomized Multi center Double masked Vehicle controlled phase 1 phase 2 Study to Evaluate the Safety Tolerability and Efficacy of OTX CSI for Intracanalicular Use for the Treatment of Subjects With Dry Eye Disease | $121,235 | 0 | 27 |
| Intracanalicular Dexamethasone used in conjunction with Restasis (cyclosporine ophthalmic emulsion) for the treatment of signs and symptoms of dry eye disease as compared to Restasis with Lotemax (loteprednol etabonate ophthalmic suspension 0.5%) and Restasis monotherapy | $113,662 | 0 | 3 |
| Evaluation of Vision Recovery and Comfort Index in Patients with Borderline/Mild Dry Eyes Undergoing Femtosecond Laser-Assisted Cataract Surgery with Premium Intraocular Lens | $110,928 | 0 | 5 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Richard Lindstrom, M.d, M.D | Ophthalmology | Bloomington, MN | $1.5M | $0 |
| Jeffrey Heier | Ophthalmology | Boston, MA | $1.2M | $0 |
| Dr. Andrew Moshfeghi, Md, MD | Ophthalmology | Los Angeles, CA | $647,092 | $0 |
| Peter Kaiser, Md, MD | Ophthalmology | Cleveland, OH | $473,059 | $0 |
| Dr. Jai Parekh, M.d, M.D | Ophthalmology | Woodland Park, NJ | $260,354 | $0 |
| Baruch Kuppermann, Md, MD | Ophthalmology | Irvine, CA | $242,655 | $0 |
| Darius Moshfeghi, Md, MD | Ophthalmology | Palo Alto, CA | $193,199 | $0 |
| Dr. Anita Campbell, M.d, M.D | Ophthalmology | Wichita, KS | $111,596 | $0 |
| Dr. Peter Kaiser, M.d, M.D | Specialist | Phoenix, AZ | $110,971 | $0 |
| Dr. Dilsher Dhoot, M.d, M.D | Retina Specialist | Santa Barbara, CA | $106,829 | $0 |
| Dr. Arshad Khanani, M.d, M.D | Ophthalmology | Reno, NV | $86,109 | $0 |
| Dr. Anthony Realini, M.d, M.D | Ophthalmology | Morgantown, WV | $82,540 | $0 |
| Frank Bucci, Md, MD | Ophthalmology | Wilkes Barre, PA | $63,713 | $0 |
| Dr. Joseph Kavanagh, M.d, M.D | Ophthalmology | Seguin, TX | $61,682 | $0 |
| Dr. Carl Awh, M.d, M.D | Ophthalmology | Nashville, TN | $59,836 | $0 |
| Kuldev Singh, Md, MD | Ophthalmology | Stanford, CA | $58,914 | $0 |
| Inder Singh | Ophthalmology | Racine, WI | $56,372 | $0 |
| David Eichenbaum, M.d, M.D | Retina Specialist | St Petersburg, FL | $45,634 | $0 |
| Forrest Swann, Md, MD | Ophthalmology | Waco, TX | $41,189 | $0 |
| Carl Danzig, M.d, M.D | Ophthalmology | Bonita Springs, FL | $38,808 | $0 |
| Alice Epitropoulos, M.d, M.D | Ophthalmology | Columbus, OH | $37,926 | $0 |
| Dr. Alan Dunton, M.d, M.D | Internal Medicine | Staten Island, NY | $34,894 | $0 |
| Dr. Lisa Feulner, M.d., Ph.d, M.D., PH.D | Specialist | Bel Air, MD | $34,251 | $0 |
| Dr. Mitchell Jackson, Md, MD | Ophthalmology | Lake Villa, IL | $34,172 | $0 |
| John Hovanesian, M.d, M.D | Ophthalmology | Laguna Hills, CA | $33,277 | $0 |
Ad
Top Products
- DEXTENZA $8.8M
- ReSure Sealant $381,012
Associated Products (2)
- DEXTENZA $8.8M
- ReSure Sealant $381,012
Payment Categories
- Food & Beverage $450,517
- Consulting $2.5M
- Travel & Lodging $87,372
- Research $23.3M
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. has made $30.2M in payments to 4,678 healthcare providers, recorded across 16,572 transactions in the CMS Open Payments database. In 2024, the company paid $10.9M. The top product by payment volume is DEXTENZA ($8.8M).
Payments were distributed across 48 medical specialties. The top specialty by payment amount is Ophthalmology ($6.3M to 2,944 doctors).
Payment categories include: Food & Beverage ($450,517), Consulting ($2.5M), Research ($23.3M), Travel & Lodging ($87,372).
Ocular Therapeutix, Inc. is associated with 2 products in the CMS Open Payments database.